B. Riley Comments on Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities researchers at B. Riley issued their Q1 2025 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Thursday, March 13th. B. Riley analyst M. Mamtani expects that the company will post earnings of ($0.03) per share for the quarter. B. Riley has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

Several other research analysts have also weighed in on LCTX. Maxim Group lowered their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. D. Boral Capital reissued a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX opened at $0.48 on Monday. The firm has a market cap of $106.18 million, a price-to-earnings ratio of -4.01 and a beta of 1.21. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61. The business’s 50 day moving average is $0.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter valued at $46,000. Two Sigma Advisers LP lifted its position in shares of Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after buying an additional 65,864 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth $152,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth $519,000. Finally, Deutsche Bank AG lifted its position in shares of Lineage Cell Therapeutics by 196.0% during the 4th quarter. Deutsche Bank AG now owns 174,702 shares of the company’s stock worth $87,000 after buying an additional 115,672 shares during the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.